Johnson & Johnson fast-tracking its Ebola efforts with Crucell and Bavarian Nordic

4 September 2014

US health care giant Johnson & Johnson (NYSE: JNJ) will fast-track the development of an Ebola vaccine in response to the current outbreak of the disease.

The combination program features a prime-boost regimen, where one vector is used to prime and the other to boost the immune response. It is composed of two vaccine components that are based on AdVac technology from Crucell NV (part of J&J’s Europe-based subsidiary Janssen), and the MVA-BN technology from Danish biotech company Bavarian Nordic.

The program has also received direct funding and uses preclinical services from the National Institute of Allergy and Infectious Diseases. Crucell will bring the development program forward, in collaboration with the Institute and Bavarian Nordic, to start human trials in early 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK